Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider
September 20, 2024 09:53 ET
|
SNS Insider pvt ltd
Pune, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA) Market Size & Growth Analysis: According to SNS Insider, The Geographic Atrophy Market was valued at USD 23.7 billion in 2023...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
September 05, 2024 10:52 ET
|
Boehringer Ingelheim
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
June 27, 2024 08:49 ET
|
Spherix Global Insights
Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That...
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
May 01, 2024 14:17 ET
|
Spherix Global Insights
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
December 14, 2023 12:58 ET
|
Spherix Global Insights
Exton, PA, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy,...
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
July 28, 2023 12:26 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic...
Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients
June 28, 2023 13:32 ET
|
Spherix Global Insights
Exton, Pennsylvania, June 28, 2023 (GLOBE NEWSWIRE) -- With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy (GA), patients...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 05, 2023 06:00 ET
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...
RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence
April 21, 2023 03:00 ET
|
RetinAI Medical AG
BERN, Switzerland and BOSTON, April 21, 2023 (GLOBE NEWSWIRE) -- RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial...
Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD
March 06, 2023 08:30 ET
|
Novelmed Therapeutics Inc
---Single therapy for multiple forms of Age-Related Macular Degeneration (AMD) NM3086 is a highly potent Alternative Pathway (AP) blocker that does not affect the Classical Pathway (CP).Dysfunction...